
CJC-1295 Ipamorelin – 5/5mg
Peptide Combination Special Ipamorelin (5mg x 5 Vials) and Mod GRF 1-29 (5mg x 5 Vials)
CJC-1295 / Ipamorelin Blend
Primary Application: Dual-Pathway Pituitary Synergy and Accelerated Recovery
Fundamental Information
-
Components: CJC-1295 (No DAC) and Ipamorelin
-
Classification: GHRH Analog (CJC) and Selective Ghrelin Receptor Agonist (Ipamorelin)
-
Mechanism: Dual-pathway pituitary stimulation
-
Primary Benefit: Pulse amplification and duration extension
Detailed Overview
The combination of CJC-1295 and Ipamorelin is one of the most widely researched synergistic peptide duos for optimizing growth hormone production. While both peptides encourage the pituitary gland to release more hormone, they do so through entirely different biological receptors. CJC-1295 mimics the signal from the hypothalamus (GHRH) to start a pulse, while Ipamorelin mimics the hormone ghrelin to amplify that pulse and block somatostatin—the body’s “brake” hormone that usually stops growth hormone release.
Studies suggest that when these two peptides are used together, they produce a synergistic effect that can result in a 3-fold to 5-fold increase in growth hormone output compared to using either peptide alone. This “nudge and amplify” approach is highly valued in research for its ability to improve muscle fiber development, accelerate fat loss through lipolysis, and enhance collagen production for joint health. Notably, the blend is researched for its high safety profile; Ipamorelin is highly selective and does not cause the spikes in cortisol (stress) or prolactin (appetite/mood) that are common with older growth-stimulating compounds. This makes the blend a centerpiece of research into long-term hormone optimization and healthy aging.
Scientific References
-
Perez B. “The Mechanism of Action and Synergy of CJC-1295 And Ipamorelin Peptide Blend.” Iconic Research And Engineering Journals. 2026.
-
Alba M, et al. “Partial reversibility of growth hormone (GH) deficiency in the GH-releasing hormone (GHRH) knockout mouse by postnatal treatment with a GHRH analog.” Endocrinology. 2005.
-
Ionescu M, Frohman LA. “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295.” Journal of Clinical Endocrinology and Metabolism. 2006.



